Glutamate decarboxylase antibodies (GADA) are commonly detected in adults with autoimmune diabetes, but the risk associated with single GADA positivity has been unclear. Findings presented at EASD 2025 provide new evidence on long-term progression in this population.

Data from the Bart’s Oxford family study included 6115 adult relatives, among whom 199 were GADA positive, with 150 (75%) being single GADA positive. Participants were followed for a median of 10.8 years. Diabetes progression occurred in 27% of GADA positive relatives, compared with 5% of antibody-negative individuals. 

Cox proportional hazards modeling revealed that single GADA positive adults had a 12% 10-year risk of diabetes, approximately six times higher than antibody negatives. Elevated GADA levels further stratified risk: individuals with GADA ≥450 DK U/ml faced a 39% 10-year risk, comparable to multiple antibody positivity.

These findings underscore the importance of monitoring single GADA positive adults, particularly those with high antibody levels, and suggest they may be suitable candidates for diabetes prevention studies.